ENGENE
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
ENGENE
Social Links:
Industry:
Biotechnology Diabetes Genetics Health Care
Founded:
1999-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.engene.com
Total Employee:
51+
Status:
Active
Contact:
604-221-4362
Email Addresses:
[email protected]
Total Funding:
33.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Content Delivery Network Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail ReCAPTCHA
Similar Organizations
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - enGene
Lumira Ventures
Lumira Ventures investment in Venture Round - enGene
Forbion Capital Partners
Forbion Capital Partners investment in Series B - enGene
Lumira Ventures
Lumira Ventures investment in Series B - enGene
Inbio Ventures
Inbio Ventures investment in Series B - enGene
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series B - enGene
Pharmstandard
Pharmstandard investment in Series B - enGene
Lumira Ventures
Lumira Ventures investment in Venture Round - enGene
RBC Capital Markets
RBC Capital Markets investment in Series A - enGene
Adams, Harkness & Hill Technology Ventures
Adams, Harkness & Hill Technology Ventures investment in Series A - enGene
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-17 | enGene Appoints James C. Sullivan, PhD as Chief Scientific Officer |
Official Site Inspections
http://www.engene.com Semrush global rank: 7.57 M Semrush visits lastest month: 458
- Host name: 79.1.212.35.bc.googleusercontent.com
- IP address: 35.212.1.79
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "enGene"
enGene - Crunchbase Company Profile & Funding
EnGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal …See details»
enGene - LinkedIn
EnGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming genetic medicines. We are unlocking the promise of gene therapy for more patients through localized delivery of non ...See details»
enGene - Overview, News & Similar companies | ZoomInfo.com
EnGene Reports Second Quarter 2024 Financial Results and Provides a Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, …See details»
enGene - 2025 Company Profile, Funding & Competitors - Tracxn
EnGene is a public company based in Saint laurent (Canada), founded in 1999 by Anthony Cheung. It operates as a Developer of oral non-viral gene therapy platform. enGene has …See details»
enGene Appoints Alex Nichols, PhD as President and Chief
Feb 2, 2023 Engene has developed scalable GMP-compliant manufacturing of DDX products. ... Organization Profile. enGene. Contact Cision. 866-245-2317 from 8 AM - 10 PM ET Contact UsSee details»
enGene - About Us - Boldly Focused on Patient Needs
The passionate experts at enGene have extensive experience in drug development and commercialization. We are boldly focused on patient needs.See details»
enGene Holdings Inc. (ENGNW) Company Profile & Overview
Mar 3, 2025 enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from …See details»
enGene - Org Chart, Teams, Culture & Jobs | The Org
View enGene's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
EnGene - adMare Bio
EnGene is leader in nucleotide delivery to the intestine. The company has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via …See details»
enGene Announces the Resignation of its Chief Medical Officer
1 day ago BOSTON & MONTREAL, June 04, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, …See details»
Contact Us - enGene
Canada 4868 Rue Levy, Suite 220 Saint-Laurent, QC, Canada H4R 2P1. United States 200 Fifth Avenue, Suite 4020 Waltham, MA 02451See details»
enGene Announces Leadership Succession Plan - Newswire
Feb 14, 2024 enGene is a late-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, whose lead program …See details»
enGene Announces the Resignation of its Chief Medical Officer
1 day ago BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, …See details»
enGene injects new hope into the future of bladder cancer care
Dec 24, 2024 Second, enGene's product, detalimogene, is an elegant, highly differentiated therapy. It's designed for community urologists and offers competitive efficacy with best-in …See details»
enGene Reports Full Year 2024 Financial Results and Provides a …
Dec 19, 2024 enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the …See details»
enGene - Funding, Financials, Valuation & Investors - Crunchbase
EnGene is a biotechnology company develops treatment for mucosal diseases through inducing therapeutic proteins of harmful proteins. New. Resources. ... How much funding has this …See details»
enGene Announces the Resignation of its Chief Medical Officer
1 day ago enGene Holdings Inc. (Nasdaq: ENGN or 'enGene' or the 'Company'), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his …See details»
Careers - enGene
The amazing enGene team is mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to …See details»
enGene - Clinical Development Pipeline
The projects are funded by enGene but are the full responsibility of the recipient grantee organization. enGene has no influence over any aspect of the project. Download the form , …See details»
enGene - Our Science
Overcoming the limitations of viral gene therapy. Mucosal tissues, such as the bladder, lungs, and gut, make up a large part of the human body. Although gene therapies have shown great …See details»